Background and objectives Although percutaneous liver biopsy (PLB) is the gold standard for staging hepatic fibrosis in hemodialysis patients with chronic hepatitis C (CHC) before renal transplantation or antiviral therapy, concerns exist about serious postbiopsy complications. Using transient elastography (TE, Fibroscan) to predict the severity of hepatic fibrosis has not been prospectively evaluated in these patients.
Introduction
Despite the introduction of blood product screening and universal precautions, hepatitis C virus (HCV) infection remains a significant threat for hemodialysis patients. The annual incidence and prevalence rates of HCV infection range from 0.22 to 6.20% and 3.4 to 80%, respectively, by different geographic distributions (1) (2) (3) (4) (5) . Although hemodialysis patients with chronic HCV infection are usually asymptomatic with mildly elevated serum alanine aminotransferase (ALT) levels, previous studies indicate that they are at increased risk of liver-related morbidity and mortality, either at the dialysis or postrenal transplantation stage (6 -8) .
In clinical practice, assessing hepatic fibrosis for hemodialysis patients with chronic hepatitis C (CHC) can help evaluate the eligibility for renal transplantation, the necessity for IFN-based therapy, the longterm prognosis, and complications related to portal hypertension and hepatocellular carcinoma (1,9 -13) , and percutaneous liver biopsy (PLB) is recognized as the gold standard to evaluate the severity of hepatic fibrosis (14, 15) . However, PLB is an invasive procedure with poor patient acceptance and, although rare, possible adverse events in hemodialysis patients (16 -20) . In addition, sampling and interpretation variability is frequently encountered, leading to the search for noninvasive means to assess the severity of hepatic fibrosis in these patients (21, 22) .
Recent studies have focused on using simple biochemical indices to predict the severity of hepatic fibrosis in uremic and nonuremic patients with CHC, and the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) was considered useful (17, (23) (24) (25) (26) (27) (28) . Nevertheless, studies for hemodialysis patients showed that the major strength of APRI was to exclude significant hepatic fibrosis, and only 50% patients could be correctly diagnosed (27, 28) . Therefore, efforts to improve the overall diagnostic accuracy through other noninvasive tools are needed.
Transient elastography (TE, Fibroscan) is a novel noninvasive tool to assess the severity of hepatic fibrosis by liver stiffness measurement (LSM). TE can be easily performed in our daily practice with immediate results and good reproducibility (29 -31) . The performance of TE to evaluate the severity of hepatic fibrosis has been validated in nonuremic patients with CHC, showing good diagnostic accuracy in those with significant hepatic fibrosis (cut-off point: 7.1 and 8.8 kPa), and excellent diagnostic accuracy in those with advanced hepatic fibrosis (cut-off point: 9.5 and 9.6 kPa) or cirrhosis (cut-off point: 12.5 and 14.6 kPa) (31) (32) (33) . However, little is known about the role of TE to assess the severity of hepatic fibrosis in hemodialysis patients with CHC. The aim of this study was to prospectively compare the diagnostic accuracy of TE and APRI for the severity of hepatic fibrosis in hemodialysis patients with CHC, taking PLB as the reference standard.
Materials and Methods

Patients
From July 2007 to March 2010, 304 consecutive hemodialysis patients with CHC aged between 18 and 65 years were prospectively enrolled at four academic centers in Taiwan. Hemodialysis patients with CHC were defined as patients with creatinine clearance of less than 10 ml/min per 1.73 m 2 of body surface area who received maintenance renal replacement therapy through vascular routes and were both positive for anti-HCV (Abbott HCV EIA 3.0, Abbott Diagnostic, Chicago, IL) and HCV RNA (Cobas TaqMan HCV Test v2.0; Roche Diagnostics, Mannheim, Germany; detection limit: 15 IU/ml) for more than 6 months. Patients who had a history of hepatitis B virus or HIV coinfection, alcohol abuse, neoplic diseases, or other causes of liver diseases, received immunosuppressive agents, had decompensated cirrhosis, declined, or were contraindicated for PLB and failed to reach LSMs were excluded from this study. The study conformed to the principles of Helsinki Declaration and was approved by the institutional review board. Each participant gave written informed consent before enrollment.
Concise Methods
Baseline demographic data were collected for all patients. Hemogram (including hemoglobin, white blood cell count, and platelet count), coagulation profiles (prothrombin time), serum biochemical data (including albumin, total bilirubin, AST, ALT, and creatinine), serologic and virological data (anti-HCV, HBsAg, anti-HIV, HCV RNA, and HCV genotype), and gray-scaled abdominal ultrasonography were performed before PLBs. The hemogram and the routine biochemistry were evaluated by automated Sysmex XE-2100 hematology analyzer (Sysmex, Kobe, Japan) and Toshiba TBA-120 FR analyzer (Toshiba, Tokyo, Japan). HCV RNA and HCV genotyping (InnoLiPA HCV II; Innogenetics, Ghent, Belgium) were tested for all patients. The APRI was calculated as AST/upper limit of normal (ULN) ϫ 100/platelet count (10 9 /L) (23). LSM was determined by TE (Fibroscan, Echosens, Paris, France; detection range: 2.5 to 75 kPa) equipped with an M probe for patients after an overnight fasting of at least 8 hours. In addition, all patients received hemodialysis 1 day before LSMs to keep adequate dry weight. All LSMs were performed by four experienced operators (K. L. She, L. F. Wu, C. C. Chen, and Y. L. Tang) who had performed more than 500 LSMs. The procedure was done with the patients lying in a supine position with the right arm tucked behind the head to facilitate probe access. The tip of the probe was placed on the skin of the right intercostal space at the level of right hepatic lobe where PLB would be performed. The volume of LSM approximates a cylinder 4 cm long and 1 cm wide between 25 and 65 mm deep below the skin surface. The results of LSM were expressed in kPa with a median value of at least 10 valid measurements and a successful rate of more than 60%. LSM failure was defined as zero valid measurement, and unreliable examinations were defined as less than 10 valid measurements, a successful rate of less than 60%, or the interquartile range (IQR) more than 30% of the median LSM value (34) .
After receiving blood tests and LSMs, all of the eligible patients underwent PLBs in 2 weeks. Ultrasound-guided liver biopsies from the right hepatic lobe were performed by 16-gauge biopsy needles (Temno Evolution, Allegiance, McGaw Park, IL). The sampling tissues were fixed with formalin and stained with hematoxylin and eosin and reticulin silver (Masson trichome method). The hepatic necroinflammation and fibrosis were assessed by the METAVIR scoring system, ranging from A0 to A3 and F0 to F4, respectively (35) . Significant hepatic fibrosis, advanced hepatic fibrosis, and cirrhosis were defined as a fibrosis stage ՆF2, ՆF3, and F4. The hepatic steatosis was graded by AGA technical guidelines ranging from G0 to G3 (36) . All of the histologic samples were evaluated by one experienced pathologist who was blinded to the clinical data of the patients.
Statistical Analyses
Statistical analyses were performed by the Statistical Program for Social Sciences (SPSS 12.0; SPSS Inc., Chicago, IL). Patient characteristics are expressed as the means Ϯ SD and percentages when appropriate. The estimated sample sizes to compare receiver operator characteristic (ROC) curves of TE and APRI in patients with a fibrosis stage ՆF2, ՆF3, and F4 were 280, 217, and 197, respectively, on the basis of the following assumptions: type I error ϭ 0.05; type II error ϭ 0.10; positive group correlation ϭ 0.43 and negative group correlation ϭ 0.50; the estimated areas under curves (AUCs) for TE and APRI ϭ 0.89 and 0.83 for a fibrosis stage ՆF2, 0.93 and 0.87 for a fibrosis stage ՆF3, and 0.97 and 0.92 for a fibrosis stage ϭ F4 (28, 37) . One-way ANOVA was used to compare the mean LSM by various fibrosis stages. The Spearman rank correlation coefficient was used to analyze the correlations between LSM and fibrosis stages. ROC curves for TE and APRI were constructed, and the AUCs of TE and APRI with 95% confidence intervals (CI) were compared by c-statistics for different fibrosis stages (37) . The adjusted uniform AUC and the naturally-observed adjusted AUC were calculated by the regression formula for the difference between the mean fibrosis stage of advanced minus nonadvanced fibrosis (DANA) (30, 38) . The sensitivity, specificity, positive and negative predictive value, positive and negative likelihood ratios (LRϩ and LRϪ), and diagnostic accuracy of LSM and APRI were determined by the known selected cut-off values (23, 32, 33 
Results
Patient Characteristics
Of 304 patients, 20 were excluded from the study because of hepatitis B virus coinfection in six, hepatocellular carcinoma in two, decompensated cirrhosis in two, failed LSM in seven (2.3%), and declining PLB in three. 
Correlation between LSM and METAVIR Fibrosis Scores
The mean LSM paralleled the advancing hepatic fibrosis: 3.6 Ϯ 0.7 kPa (F0), 4.5 Ϯ 1.3 kPa (F1), 6.6 Ϯ 1.1 kPa (F2), 8.9 Ϯ 0.9 kPa (F3), and 15.1 Ϯ 7.8 kPa (F4) (P Ͻ 0.001). Figure 1 shows the box plots of LSM for each METAVIR fibrosis stage. The median LSM and the fibrosis stages were highly correlated: 3.3 kPa (2.8 to 5.8 kPa) (F0), 4.3 kPa (2.5 to 8.7 kPa) (F1), 6.4 kPa (4.8 to 11.8 kPa) (F2), 8.9 kPa (5.7 to 10.1 kPa) (F3), and 11.5 kPa (9.3 to 35.8 kPa) (F4) (r ϭ 0.81, P Ͻ 0.001). Figure 2 shows the diagnostic accuracy of TE and APRI to predict patients with significant hepatic fibrosis, advanced hepatic fibrosis, and cirrhosis. The AUC of TE was superior to that of APRI in patients with a fibrosis stage ՆF2 Table 2 shows the selected LSM cut-off values to predict patients with significant hepatic fibrosis, advanced hepatic fibrosis, or cirrhosis. To predict patients with ՆF2, the sensitivity and specificity were 55 and 96% when the LSM was set at 7.1 kPa, and 30 and 100% when the LSM was set at 8.8 kPa; the sensitivity and specificity were 93 and 88% when the optimized LSM was set at 5.3 kPa. To predict patients with ՆF3, the sensitivity and specificity were 45 and 99% when the LSM was set at 9.5 and 9.6 kPa; the sensitivity and specificity were 95 and 99% when the optimized LSM was set at 8.3 kPa. To predict patients with F4, the sensitivity and specificity were 36 and 100% when the LSM was set at 12.5 kPa and 29 and 100% when the LSM was set at 14.6 kPa; the sensitivity and specificity were 100 and 96% when the optimized LSM was set at 9.2 kPa. Furthermore, the sensitivity and specificity of APRI for those with ՆF2, ՆF3, and F4 were 74 and 82%, 93 and 90%, and 100 and 85% when the optimized cut-off values were set at 0.55, 0.75, and 0.80, respectively. Choosing the optimized LSM cut-off values of 5.3, 8.3, and 9.2 kPa, 254 (87%), 281 (97%), and 270 (93%) of the 291 patients (284 patients plus seven patients with failed LSM) with a fibrosis stage of ՆF2, ՆF3, and F4 were correctly diagnosed without PLB, respectively.
Diagnostic Accuracy of TE and APRI in Patients with Significant Hepatic Fibrosis, Advanced Hepatic Fibrosis, and Cirrhosis
Selected Cut-off Values of LSM and APRI for Patients with Significant Hepatic Fibrosis, Advanced Hepatic Fibrosis, and Cirrhosis
Univariate Analysis of Baseline Factors to Predict LSM Accuracy on Optimized Cut-off Values
When the optimized cut-off values of LSM were set at 5.3 and 9.2 kPa, we performed univariate analysis to find baseline factors influencing the LSM accuracy in patients with a fibrosis stage of ՆF2 and F4. The body weight (P ϭ 0.02) was significantly associated with LSM accuracy to predict patients with a fibrosis stage of ՆF2; BMI (P ϭ 0.09), AST level (P ϭ 0.12), ALT level (P ϭ 0.09), and hepatic activity score (P ϭ 0.11) had borderline significance. Furthermore, the hepatic activity score (P ϭ 0.01) was significantly associated with LSM accuracy to predict patients with a fibrosis stage of F4; BMI (P ϭ 0.17) and ALT level (P ϭ 0.16) had borderline significance.
Discussion
The use of simple noninvasive tests to assess the severity of hepatic fibrosis in patients with chronic liver diseases has gained popularity because invasive PLB bears adverse events and interpretation errors. Applying a useful noninvasive tool to replace PLB is even more appealing both for practicing physicians and hemodialysis patients because the platelet dysfunction in hemodialysis patients may potentially cause serious bleeding (19, 20) . Although prior studies have shown that APRI can be used to evaluate the severity of hepatic fibrosis in hemodialysis patients with CHC, the results clearly indicated that the merit of APRI is to exclude patients with significant hepatic fibrosis, leaving about half of the patients with uncertain severity of hepatic fibrosis (27, 28) . By comparing the AUCs between TE and APRI, our study showed that the diagnostic performance of TE was better than that of APRI in hemodialysis patients with a fibrosis stage of ՆF2 and ՆF3. Although the AUC of TE was higher than that of APRI to predict patients with cirrhosis, they were not statistically significant, probably because of small cirrhotic patient numbers. These findings are in line with the observations in nonuremic patients with CHC (32) .
Although the LSM in hemodialysis patients with fibrosis stages of F0 and F1 showed significant overlap from the box plot, it had excellent power to discriminate those with fibrosis stages of F1 to F4. The AUC of our patients was higher than that of nonuremic patients in predicting a fibrosis stage ՆF2 (0.96 versus 0.79 and 0.83) or ՆF3 (0.98 versus 0.91 and 0.90) and was comparable with these studies in predicting F4 (0.99 versus 0.97 and 0.95) (32, 33) . Because the variability of AUC is related to the prevalence of different fibrosis stages, the AUCs should be adjusted by the population-based sampling (38) . After AUC standardization for different fibrosis stages, the AUC of our patients with a fibrosis stage ՆF2 still reached 0.98 to 1.00. Therefore, the possible distribution bias could be minimized. Although applying the known LSM cut-off values for nonuremic patients with a fibrosis stage of ՆF2 (7.1 and 8.8 kPa), ՆF3 (9.5 and 9.6 kPa), and F4 (12.5 and 14.6 kPa) to predict the severity of hepatic fibrosis in hemodialysis patients had excellent specificity and positive predictive value, these cut-off values could only cover a small portion of patients, which may lessen the clinical usefulness. However, when we adjusted the optimized cut-off values to 5.3, 8.3, and 9.2 kPa, more patients with a fibrosis stage of ՆF2, ՆF3, and F4 who had LSMs greater than the cut-off values could be covered, and the overall diagnostic accuracy was increased. Furthermore, the optimized APRI cut-off values to predict the severity of hepatic fibrosis should also be lowered to improve the diagnostic accuracy (27, 28) .
Compared with previous studies, the different diagnostic accuracy and optimized cut-off values of LSM in our study may be explained by the following factors: the distribution of fibrosis stages in hemodialysis patients was different from that in nonuremic patients, which may introduce a spectrum bias into the analysis and influence the overall AUCs (38, 39) ; our patients received hemodialysis before LSM to keep adequate dry weight, which might decrease the portal and central venous pressure (40,41); our patients had fasted overnight, which might lessen the increased portal blood flow after food intake and thereby affect LSM (42); and our patients had lower baseline ALT levels and necroinflammatory activity, which may decrease the inaccurate LSM rates (43) . However, we believed that the introduction of spectrum bias was the key factor for such differences.
The usefulness of TE to assess the severity of hepatic fibrosis in hemodialysis patients with CHC was demonstrated, with higher diagnostic accuracy and a lower measurement failure rate (2.3%) compared with the general population (31) . The lower measurement failure rate was attributed to the lower BMI, younger age, and experienced operators who performed LSMs (34) . However, limitations still existed. We assumed that PLB, which takes 1/50,000 the size of the liver, is the gold standard for staging hepatic fibrosis. However, we adopted the strict criteria to ensure adequate sample length, portal tract numbers, and sample interpretation to minimize interpretation errors. 
Conclusions
TE is superior to APRI in assessing the severity of hepatic fibrosis in hemodialysis patients with CHC, and applying this simple noninvasive tool can substantially decrease the need of staging PLB.
